Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.78 |
| ▸ | DDB1 | Q16531 | 12/20 | 0.78 |
| ▸ | STAT3 | P40763 | 2/20 | 0.64 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.61 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.61 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.61 |
| ▸ | TNF | P01375 | 1/20 | 0.55 |
| ▸ | IL1B | P01584 | 1/20 | 0.55 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.55 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.55 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | SNCA | P37840 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23651730 | 0.93 | CRBN (0.68) | CRBNDDB1STAT3HDAC1HDAC6 | |
| SCHEMBL23015900 | 0.93 | CRBN (0.68) | CRBNDDB1STAT3HDAC1HDAC6 | |
| SCHEMBL21163040 | 0.93 | CRBN (0.75) | CRBNDDB1STAT3HDAC1HDAC6 | |
| SCHEMBL22136180 | 0.91 | CRBN (0.73) | CRBNDDB1STAT3HDAC1HDAC6 | |
| SCHEMBL26528499 | 0.91 | CRBN (0.75) | CRBNDDB1STAT3HDAC1HDAC6 | |
| SCHEMBL26320196 | 0.91 | STAT3 (0.76) | CRBNDDB1STAT3HDAC1HDAC6 | |
| SCHEMBL19308923 | 0.90 | CRBN (0.80) | CRBNDDB1STAT3HDAC1HDAC6 | |
| SCHEMBL23770363 | 0.90 | CRBN (0.71) | CRBNDDB1STAT3HDAC1HDAC6 | |
| SCHEMBL23584020 | 0.90 | CRBN (0.71) | CRBNDDB1STAT3HDAC1HDAC6 | |
| SCHEMBL18379831 | 0.90 | CRBN (0.71) | CRBNDDB1STAT3HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024107763-A1 | N6-ADENOSINE-METHYLTRANSFERASE PROTACS AND METHODS OF USE THEREOF | UNIVERSITY OF ZURICH (CH) | 2024-05-23 | — | — | WO | disclosed |
| US-11730726-B2 | Dimeric immuno-modulatory compounds against cereblon-based mechanisms | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730726-B2 | Dimeric immuno-modulatory compounds against cereblon-based mechanisms | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| WO-2022086937-A9 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF ENL | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2022266491-A1 | PROTEOLYSIS TARGETING CHIMERAS AND POLYPHARMACOLOGICAL AGENTS TARGETING BCL-2, AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022086937-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF ENL | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-04-28 | — | — | WO | disclosed |
| US-11066391-B1 | Atorvastatin derived HMG-CoA reductase degradation inducing compound | UPPTHERA (KR) | 2021-07-20 | — | — | US | disclosed |
| CN-112512589-A | Dimeric immunomodulatory compounds against CEREBLON-based mechanisms | H·李·莫菲特癌症中心研究有限公司 | 2021-03-16 | — | — | CN | disclosed |
| US-10849980-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| WO-2020035049-A1 | DEGRADATION AGENTS FOR CYCLIN DEPENDENT KINASE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 中国科学院上海药物研究所 | 2020-02-20 | — | — | WO | disclosed |
| US-20190151457-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-05-23 | — | — | US | disclosed |
| US-20180085465-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2018-03-29 | — | — | US | disclosed |
| WO-2017024318-A1 | TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017024319-A1 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730726-B2 | Dimeric immuno-modulatory compounds against cereblon-based mechanisms | CRBN, CD4, CD74 | CRBN 1/4885DDB1 1404/4885STAT3 3187/4885 |
| US-11066391-B1 | Atorvastatin derived HMG-CoA reductase degradation inducing compound | HMGCR, LDLR, HMGB2 | CRBN 1054/4885DDB1 441/4885STAT3 4491/4885 |
| US-20190151457-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | CRBN 1/4885DDB1 113/4885STAT3 2989/4885 |
| US-20180085465-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | CRBN 1/4885DDB1 113/4885STAT3 2989/4885 |
| US-10849980-B2 | Methods to induce targeted protein degradation through bifunctional molecules | CRBN, MDM2, MYCBP | CRBN 1/4885DDB1 113/4885STAT3 2989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.